Schedule 13G ownership disclosure

Cytek Biosciences Inc

Common Stock · CUSIP: 23285D109

Event date: 2025-03-31

Filing-level shares
9,622,008
Percent of class
7.51%
  • The Vanguard Group

    Shares: 9,622,008 · Class: 7.51%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000932471-25-000481
Form type
SCHEDULE 13G/A
Filer
Cytek Biosciences, Inc.
CIK
CIK 1831915
Filed
Apr 30, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub